ZHX2与肿瘤的相关性研究

doi:10.3760/cma.j.issn.1673-422X.2013.12.008

摘要/Abstract

摘要： 转录抑制因子ZHX2是ZHX蛋白家族的成员之一，在人体组织中广泛存在，通过转录抑制作用参与多种疾病的发生与发展。研究表明ZHX2与肝癌、多发性骨髓瘤、胃癌、结直肠癌等的发生发展密切相关，具有肿瘤治疗的潜在价值。

Abstract: Transcription repressor ZHX2 is one of the members in ZHX protein family, which exists widely in human tissue and participates in the occurrence and development of various diseases. Researches show that ZHX2 is closely related to the occurrence and development of cancers, such as liver cancer, multiple myeloma, gastric cancer and colorectal cancer, which has the potential value of tumor treatment.

Key words: Zinc fingers, Homeodomain proteins, Neoplasms, Transcription factors

付世杰, 郭庆河. ZHX2与肿瘤的相关性研究[J]. 国际肿瘤学杂志, 2013, 40(12): 905-907.

FU Shi-Jie, GUO Qing-He. ZHX2 and cancer[J]. Journal of International Oncology, 2013, 40(12): 905-907.

参考文献

［1］ Kawata H, Yamada K, Shou Z, et al. Zincfingers and homeoboxes (ZHX) 2, a novel member of the ZHX family as a transcriptional repressor. Biochem J, 2003, 373 (Pt 3): 747757. ［2］ Shen H, Luan F, Liu H, et al. ZHX2 is a repressor of alphafetoprotein expression in human hepatoma cell lines. J Cell Mol Med, 2008, 12(68): 27722780. ［3］ Li MS, Li PF, He SP, et al. The promoting molecular mechanism of alphafetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol, 2002, 8(3): 469475. ［4］ Cavin LG, Venkatraman M, Factor VM, et al. Regulation of alphafetoprotein by nuclear factorkappaB protects hepatocytes from tumor necrosis factoralpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res, 2004, 64 (19): 70307038. ［5］ Perincheri S, Dingle RW, Peterson ML, et al. Hereditary persistence of alphafetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene. Proc Natl Acad Sci USA, 2005, 102(2): 396401. ［6］ Lv Z, Zhang M, Bi J, et al. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol, 2006, 125(5): 740746. ［7］ Kittaka N, Takemasa I, Takeda Y, et al. Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur J Cancer, 2008, 44(6): 885897. ［8］ Shirakawa H, Suzuki H, Shimomura M, et al. Glypican3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 2009, 100(8): 14031407. ［9］ Morford LA, Davis C, Jin L, et al. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alphafetoprotein regulator 2. Hepatology, 2007, 46(5): 15411547. ［10］ Maurel M, Dejeans N, Taouji S, et al. MicroRNA1291mediated silencing of IRE1α enhances Glypican3 expression. RNA, 2013, 19(6): 778788. ［11］ Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclindependent kinases, tumorsuppressor gene products, Ki67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol, 2003, 34(5): 471478. ［12］ MüllerTidow C, Metzger R, Kügler K, et al. Cyclin E is the only cyclindependent kinase 2associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res, 2001, 61(2): 647653. ［13］ Ohashi R, Gao C, Miyazaki M, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res, 2001, 21(1B): 657662. ［14］ Yue X, Zhang Z, Liang X, et al. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclin A and E. Gastroenterology, 2012, 142(7): 15591570. ［15］ Gargalovic PS, Erbilgin A, Kohannim O, et al. Quantitative trait locus mapping and identification of Zhx2 as a novel regulator of plasma lipid metabolism. Circ Cardiovasc Genet, 2010, 3(1): 6067. ［16］ Watts GS, Oshiro MM, Junk DJ, et al. The acetyltransferase p300/CBPassociated factor is a p53 target gene in breast tumor cells. Neoplasia, 2004, 6(3): 187194. ［17］ Cui R, Nguyen TT, Taube JH, et al. Family members p53 and p73 act together in chromatin modification and direct repression of alphafetoprotein transcription. J Biol Chem, 2005, 280(47): 3915239160. ［18］ Lu ZL, Luo DZ, Wen JM. Expression and significance of tumorrelated genes in HCC. World J Gastroenterol, 2005, 11(25): 38503854. ［19］ Aoki T, Miyamoto A, Marubashi S, et al. Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma. Int J Oncol, 2004, 24(2): 441446. ［20］ Legartova S, HarnicarovaHorakova A, Bartova E, et al. Expression of RAN, ZHX2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors. Neoplasma, 2010, 57(5): 482487. ［21］ Armellini A, Sarasquete ME, GarcíaSanz R, et al. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol, 2008, 141(2): 212215. ［22］魏晶晶, 吕自力, 党裔武, 等. 结直肠癌中ZHX2蛋白表达的检测及其临床病理意义. 临床与实验病理学杂志, 2012, 28(2): 128131. ［23］ Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the antiapoptotic surviving gene by wild type p53. J Biol Chem, 2002, 277(5): 32473257. ［24］ Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcription response by structurally diverse core promoters. Genes Dev, 2010, 24(2): 135147. ［25］陈其军, 吕自力, 党裔武, 等. 转录抑制因子ZHX2在胃癌组织中的表达及临床意义. 世界华人消化杂志, 2011, 19 (30): 31633167.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.